
Dr Kathryn McIntosh
Teaching Fellow
Strathclyde Institute of Pharmacy and Biomedical Sciences
Back to staff profile
VITAE International Research award Recipient 10/11/2021 Fellow of the Higher Education Academy Recipient 10/10/2016 Court Medal Recipient 25/6/2003
Prize And Awards
Back to staff profile
TAK1 is an upstream MAP 3 K regulator of a novel non-canonical NFkB pathway stimulated by IL-1b Farhan Mohammad, McIntosh Kathryn A, Cunningham Margaret R, Plevin Robin, Tinto Kirsty British Journal of Pharmacology Vol 180, pp. 708-709 (2023) https://doi.org/10.1111/bph.16110 IL-1β stimulates a novel, IKKα -dependent, NIK -independent activation of non-canonical NFκB signalling McIntosh Kathryn, Khalaf Yousif H, Craig Rachel, West Christopher, McCulloch Ashley, Waghmare Ajay, Lawson Christopher, Chan Edmond YW, MacKay Simon, Paul Andrew, Plevin Robin Cellular Signalling Vol 107 (2023) https://doi.org/10.1016/j.cellsig.2023.110684 The development of proteinase-activated receptor-2 modulators and the challenges involved McIntosh Kathryn A, Cunningham Margaret R, Bushell Trevor, Plevin Robin Biochemical Society Transactions Vol 48, pp. 2525-2537 (2020) https://doi.org/10.1042/BST20200191 Novel protective role for MAP kinase phosphatase 2 in inflammatory arthritis Schroeder Juliane, Ross Kirsty, McIntosh Kathryn, Jabbar Shilan Khayrula Jabbar, Woods Stuart, Crowe Jenny, Patterson-Kane Janet C, Alexander James, Lawrence Catherine, Plevin Robin RMD Open Vol 5, pp. e000711 (2019) https://doi.org/10.1136/rmdopen-2018-000711 Inhibition of cytokine-mediated JNK signalling by purinergic P2Y11 receptors, a novel protective mechanism in endothelial cells Ng Pei Y, McIntosh Kathryn A, Hargrave Gillian, Ho Ka H, Paul Andrew, Plevin Robin Cellular Signalling Vol 51, pp. 59-71 (2018) https://doi.org/10.1016/j.cellsig.2018.07.016 Inhibitory Kappa B kinase α (IKKα) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers Anthony Nahoum G, Baiget Jessica, Berretta Giacomo, Boyd Marie, Breen David, Edwards Joanne, Gamble Carly, Gray Alexander I, Harvey Alan L, Hatziieremia Sophia, Ho Ka Ho, Huggan Judith K, Lang Stuart, Llona-Minguez Sabin, Luo Jia Lin, McIntosh Kathryn, Paul Andrew, Plevin Robin J, Robertson Murray N, Scott Rebecca, Suckling Colin J, Sutcliffe Oliver Brook, Young Louise C, MacKay Simon P Journal of Medicinal Chemistry Vol 60, pp. 7043-7066 (2017) https://doi.org/10.1021/acs.jmedchem.7b00484
Publications
Back to staff profile
Interleukin-1b stimulates a novel early activation of non-canonical NF Kappa B signalling pathway linked to CXCL12 production Speaker 13/9/2022
Developing novel inhibitors to prevent the induction of CXCL12 in breast cancer fibroblasts cells McIntosh, Kathryn (Principal Investigator) CXCL12 plays an important role in a number of diseases. In cancer it has a key role in sustaining the tumour microenvironment and is implicated in ovarian and breast cancers. One strategy is to develop new drugs that block the formation of CXCL12 prior to the activation of its receptor CXCR4. A screen conducted through SULSA-Biocity has lead to 50 propriety compounds to be taken forward for testing. 28-Jan-2022 - 29-Jan-2026 Development and preclinical validation of novel PAR2 inhibitors for the treatment of Osteoarthritis McIntosh, Kathryn (Principal Investigator) Crilly, Anne (Co-investigator) Jamieson, Craig (Co-investigator) Plevin, Robin (Co-investigator) Rattray, Zahra (Co-investigator) 01-Jan-2020 - 30-Jan-2022 Preventing the damaging effects of cancer chemotherapy and radiation treatment on human endothelial cells targeting the JNK pathway Plevin, Robin (Principal Investigator) Boyd, Marie (Co-investigator) McIntosh, Kathryn (Co-investigator) Preventing the damaging effects of cancer chemotherapy and radiation treatment on human endothelial cells targeting the JNK pathway 01-Jan-2019 - 31-Jan-2023 Inhibition of human CXCL12 expression by novel inhibitory kappa B kinase alpha compounds - a novel approach for new drug development in breast cancer McIntosh, Kathryn (Principal Investigator) Patton, Chloe (Post Grad Student) 08-Jan-2018 - 31-Jan-2021 Investigating the role of the non-canconical arm of the NFkB pathway in pancreatic cancer, utilising novel inhibitory compounds. McIntosh, Kathryn (Principal Investigator) The NFkB pathway is an important transcription factor pathway involved in the regulation of a large number of cellular processes. While the canonical arm of this pathway has been studied extensively the non-canonical arm has been largely overlooked. Is has however been implicated in cell growth, proliferation and survival in cancer, therefore inhibiting components of this pathway is an attractive therapeutic approach to regulating cancer disease progression [3]. We have synthesised selective inhibitors of the kinases IKKa, and NIK which require further pharmacological characterisation, and their use will develop our understanding of the role of these kinases in cancer. 01-Jan-2018 - 02-Jan-2019 Development of novel PAR2 antagonists to treat inflammatory disease McIntosh, Kathryn (Principal Investigator) Based on the recently published PAR2 crystal structure, a novel series of PAR2 antagonists were developed - namely the AZ series. However these require further target validation and elucidation of there pharmacological properties, and from these novel derivatives will be developed. 05-Jan-2018 - 29-Jan-2025
Research Interests
Current Collaborators:
CXCL12-IKKa project = Professor Valerie Speirs (University of Aberdeen) and Dr Craig Jamieson (UoS)
PAR2-Osteoarthrits project = Professor Robin Plevin (UoS), Dr Anne Crilly (University of the West of Scotland), Dr Craig Jamieson (UoS) and Dr Zahra Rattray (UoS)
Professional Activities
Projects
Back to staff profile
Contact
Dr
Kathryn
McIntosh
Teaching Fellow
Strathclyde Institute of Pharmacy and Biomedical Sciences
Email: kathryn.a.mcintosh@strath.ac.uk
Tel: 548 2909